Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

MicroRNA-215: From biology to theranostic applications.

Vychytilova-Faltejskova P, Slaby O.

Mol Aspects Med. 2019 Mar 26. pii: S0098-2997(19)30001-9. doi: 10.1016/j.mam.2019.03.002. [Epub ahead of print] Review.

PMID:
30904345
2.

Long Non-Coding RNAs in Multiple Myeloma.

Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R.

Noncoding RNA. 2019 Jan 24;5(1). pii: E13. doi: 10.3390/ncrna5010013. Review.

3.

MicroRNA isolation and quantification in cerebrospinal fluid: A comparative methodical study.

Kopkova A, Sana J, Fadrus P, Machackova T, Vecera M, Vybihal V, Juracek J, Vychytilova-Faltejskova P, Smrcka M, Slaby O.

PLoS One. 2018 Dec 7;13(12):e0208580. doi: 10.1371/journal.pone.0208580. eCollection 2018.

4.

Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.

Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):321-327. doi: 10.21873/cgp.20090.

5.

Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer.

Vychytilova-Faltejskova P, Stitkovcova K, Radova L, Sachlova M, Kosarova Z, Slaba K, Kala Z, Svoboda M, Kiss I, Vyzula R, Cho WC, Slaby O.

Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1019-1028. doi: 10.1158/1055-9965.EPI-18-0318. Epub 2018 Jul 5.

PMID:
29976566
6.

Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.

Obermannova R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, Cho WC, Sachlova M, Svoboda M, Vyzula R, Slaby O.

Anticancer Res. 2018 Jun;38(6):3719-3724. doi: 10.21873/anticanres.12651.

PMID:
29848733
7.

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9.

Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O.

Oncogenesis. 2017 Dec 4;6(11):399. doi: 10.1038/s41389-017-0006-6.

8.

miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.

Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, Deutsch A, Wulf-Goldenberg A, Adiprasito JB, Stoeger H, Haybaeck J, Svoboda M, Stotz M, Hoefler G, Slaby O, Calin GA, Gerger A, Pichler M.

Clin Cancer Res. 2017 Sep 1;23(17):5255-5266. doi: 10.1158/1078-0432.CCR-17-0023. Epub 2017 May 22.

9.

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.

Kiss I, Mlcochova J, Bortlicek Z, Poprach A, Drabek J, Vychytilova-Faltejskova P, Svoboda M, Buchler T, Batko S, Ryska A, Hajduch M, Slaby O.

Anticancer Res. 2016 Sep;36(9):4955-9.

PMID:
27630355
10.

Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.

Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, Haybaeck J, Svoboda M, Okugawa Y, Gerger A, Hoefler G, Goel A, Slaby O, Calin GA.

Clin Cancer Res. 2017 Mar 1;23(5):1323-1333. doi: 10.1158/1078-0432.CCR-16-0497. Epub 2016 Sep 6.

11.

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.

Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M.

Onco Targets Ther. 2016 Jul 28;9:4695-703. doi: 10.2147/OTT.S102891. eCollection 2016.

12.

Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer.

Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O.

Carcinogenesis. 2016 Oct;37(10):941-950. doi: 10.1093/carcin/bgw078. Epub 2016 Aug 1.

PMID:
27485599
13.

Genome-wide microRNA Expression Profiling in Primary Tumors and Matched Liver Metastasis of Patients with Colorectal Cancer.

Vychytilova-Faltejskova P, Pesta M, Radova L, Liska V, Daum O, Kala Z, Svoboda M, Kiss I, Slaby O.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):311-6.

PMID:
27365381
14.

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.

Iliev R, Stanik M, Fedorko M, Poprach A, Vychytilova-Faltejskova P, Slaba K, Svoboda M, Fabian P, Pacik D, Dolezel J, Slaby O.

Onco Targets Ther. 2016 Jan 8;9:217-22. doi: 10.2147/OTT.S91295. eCollection 2016.

15.

Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors.

Vychytilova-Faltejskova P, Slaby O.

Exp Suppl. 2015;106:75-122. doi: 10.1007/978-3-0348-0955-9_4.

PMID:
26608200
16.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M.

BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.

17.

MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.

Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova J, Kren L, Hermanova M, Lenz J, Karasek P, Vyzula R, Slaby O.

Diagn Pathol. 2015 Apr 24;10:38. doi: 10.1186/s13000-015-0272-6.

Supplemental Content

Loading ...
Support Center